Waldencast’s core business model is well-articulated around two differentiated premium brands with strong growth momentum and operational leverage. The company benefits from a resilient market with expanding TAM in premium beauty and professional skincare. Its flywheel model of reinvesting margin g…
Waldencast (WALD) Q4 2024: 29% Revenue Growth Highlights Strength of Dual-Brand Beauty Platform
Waldencast delivered robust top-line momentum driven by Milk Makeup and Obagi Medical, underscoring the resilience of premium beauty. Operational leverage expanded significantly despite strategic marketing investments, positioning the company for mid-teens growth in 2025. The Ulta Beauty launch and new product innovations are key catalysts for accelerated revenue in the coming quarters.
Summary
- Brand-Led Platform Growth: Strong dual-brand performance fuels consistent outperformance versus peers.
- Operational Efficiency Gains: Margin expansion achieved alongside elevated marketing spend to drive long-term growth.
- Acceleration Expected: Strategic product launches and expanded distribution set to accelerate revenue beyond a flat Q1.
Business Overview
Waldencast operates a multi-brand beauty platform focusing on high-growth, premium makeup and professional skincare segments. The company generates revenue primarily through its two flagship brands: Milk Makeup, a clean, culturally relevant makeup brand with a strong Gen Z following, and Obagi Medical, a physician-dispensed medical-grade skincare leader. Revenue streams are balanced across U.S. retail channels, physician dispense, and international markets, with ongoing expansion into new categories and distribution channels.
Performance Analysis
In Q4 2024, Waldencast reported comparable net revenue growth of 29.4%, reaching $72.1 million, driven by balanced contributions from Milk Makeup and Obagi Medical. Milk Makeup grew 31.9%, supported by channel expansion including initial shipments to over 600 Ulta Beauty stores and Ulta.com. Obagi Medical delivered 27.7% growth, propelled by strength in its physician-dispense channel and marketing initiatives. Adjusted gross profit increased 30.7% to $52.6 million with stable margin at 73%, reflecting effective product and channel mix management.
Adjusted EBITDA doubled year-over-year to $11.2 million, expanding margin by 530 basis points to 15.5%. This margin expansion demonstrates strong operational leverage achieved despite increased investments in marketing and international capabilities. For the full year 2024, Waldencast grew net revenue 27.5% to $273.9 million and expanded adjusted EBITDA margin by 350 basis points to 14.7%, underscoring the robustness of its flywheel business model that reinvests margin gains into growth drivers.
- Balanced Brand Contribution: Milk Makeup and Obagi Medical both delivered double-digit growth, reinforcing the platform’s diversified revenue base.
- Margin Discipline: Adjusted gross margin held steady at a premium level despite reinvestment, supporting sustainable profitability.
- Cash Flow Efficiency: Strong adjusted EBITDA to cash conversion ratio of 78.8% highlights efficient working capital and low capital expenditure needs.
Overall, these results reflect the success of Waldencast’s strategy to combine high-growth brands with operational efficiency and disciplined reinvestment, positioning the company well for continued momentum.
Executive Commentary
"We are building a global best-in-class beauty and wellness platform that creates, acquires, accelerates, and scales the next generation of high-growth, highly profitable, purpose-driven brands."
Michelle Brissett, Founder & Chief Executive Officer
"Our adjusted EBITDA margin expansion reflects strong revenue momentum and improved operational leverage, effectively offsetting strategic increased investment in marketing and international capabilities to support future sustainable growth."
Manuel Manfredi, Chief Financial Officer
Strategic Positioning
1. Dual-Brand Growth Engine
Waldencast’s core strategy centers on two high-potential brands in premium makeup and professional skincare. Milk Makeup’s cultural relevance and rapid innovation pace drive strong Gen Z engagement and international expansion. Obagi Medical leverages its physician-dispense leadership and clinical efficacy to dominate fast-growing dermatological skincare segments. This dual-brand approach balances consumer-facing mass prestige with professional endorsement, creating a resilient growth platform.
2. Operational Leverage via the Flywheel Model
The company’s flywheel effect starts with strong brand equity and structural category growth, then drives gross margin expansion through operational efficiencies. Margin gains are reinvested into sales and marketing to fuel further top-line growth, creating a virtuous cycle. In 2024, Waldencast outpaced top peers by 3.5 times in revenue growth and achieved a gross margin premium of 430 basis points, validating this model’s effectiveness.
3. Strategic Distribution Expansion
Milk Makeup’s launch into over 600 Ulta Beauty stores and Ulta.com in early 2025 marks a significant channel expansion beyond Sephora. This measured rollout prioritizes high per-store productivity over full distribution, mitigating dilution risks. Obagi Medical continues to deepen penetration in the physician-dispense channel and digital platforms, while also expanding internationally, enhancing both reach and brand awareness.
4. Innovation as a Growth Catalyst
Innovation remains a key growth lever. Milk Makeup’s recent launches include the viral Cooling Water Jelly Tint and the new Hydro Grip Skin Tint, which targets the large complexion category with a long-lasting gel formula. Obagi Medical introduced clinically backed new products like the Super Antioxidant Serum and Moisture Restore Hydration Cream, reinforcing its medical-grade skincare leadership and addressing unmet patient needs.
5. Financial and Capital Structure Strengthening
Waldencast secured a new $205 million five-year credit facility, extending debt maturity to 2030 and enhancing financial flexibility. The company maintains a net debt position of $154.2 million with $14.8 million in cash and $30 million undrawn on its revolving credit facility. Low capital expenditures and strong cash flow conversion underpin a disciplined capital allocation approach focused on growth investments and deleveraging post-regulatory expenses.
Key Considerations
Waldencast’s Q4 and full-year 2024 results highlight a company executing a clear strategy in a resilient beauty market, yet several factors warrant attention:
- Inventory and Base Effects: The flat Q1 2025 guidance reflects the anniversary of a blockbuster Milk Makeup launch and retail inventory adjustments, signaling short-term normalization rather than demand erosion.
- Marketing Investment Evolution: Marketing spend is increasing both in absolute and percentage terms, transitioning Milk Makeup from organic and influencer-driven growth to broader paid campaigns, especially with the Ulta launch.
- Channel Cannibalization Risks: The Ulta launch may cause some cannibalization of Sephora sales, though management expects net incremental growth driven by new consumer reach.
- Physician-Dispense Channel Normalization: Obagi Medical’s physician-dispense channel growth is moderating from double-digit to mid-single-digit rates, reflecting market normalization but retaining premiumization trends.
- Regulatory Expense Impact: Ongoing regulatory investigations continue to weigh on cash flow with non-recurring expenses, expected to abate and improve cash generation post-resolution.
Risks
Waldencast faces risks from evolving macroeconomic conditions that may impact consumer spending patterns despite the beauty sector’s resilience. Inventory adjustments by retailers could temporarily suppress consumption metrics. The regulatory investigation and associated costs remain an overhang on cash flow and capital allocation flexibility. Competitive pressures in makeup and professional skincare categories require sustained innovation and marketing investment to maintain growth trajectories.
Forward Outlook
For Q1 2025, Waldencast guides to relatively flat net revenue year-over-year, primarily due to the anniversary of the Milk Makeup Cooling Water Jelly Tint launch and retail inventory adjustments. Beyond Q1, management expects sequential acceleration in revenue growth driven by the continued rollout at Ulta, new product launches including Milk Makeup’s Hydro Grip Skin Tint, and Obagi Medical’s expansion in physician-dispense and digital channels.
- Full-year 2025 net revenue growth is expected in the mid-teens percentile range.
- Adjusted EBITDA margin is projected to expand further into the mid-to-high teens percentile range.
Management emphasizes confidence in sustained top-line momentum fueled by innovation and distribution expansion despite near-term headwinds.
Takeaways
Waldencast’s Q4 2024 results and outlook reveal a company successfully executing a differentiated dual-brand strategy in premium beauty, with strong operational discipline and growth reinvestment:
- Robust Growth Engine: Milk Makeup and Obagi Medical continue to outperform peers, driving nearly 30% revenue growth and margin expansion through efficient execution.
- Strategic Expansion and Innovation: The Ulta launch and new product introductions are poised to accelerate growth, particularly in complexion and skincare categories with high consumer loyalty.
- Cash Flow and Capital Flexibility: Despite regulatory-related cash flow headwinds, strong adjusted EBITDA conversion and a new credit facility provide a solid financial foundation to support growth investments.
Conclusion
Waldencast’s fourth quarter and full year 2024 performance underscore the strength of its premium beauty platform and the effectiveness of its flywheel model. The company is well positioned for accelerated growth in 2025, leveraging product innovation, expanded distribution, and operational leverage, while navigating near-term inventory and regulatory challenges.
Industry Read-Through
Waldencast’s results reinforce the resilience of the premium beauty sector amid macroeconomic normalization, highlighting the importance of brand differentiation, innovation, and channel expansion. The success of physician-dispense skincare brands like Obagi Medical signals sustained consumer demand for clinically backed, high-performance products, a trend likely to influence competitive dynamics industry-wide. Moreover, the strategic measured rollout of Milk Makeup into Ulta illustrates the critical balance between distribution expansion and productivity in makeup retail, a lesson relevant to other beauty companies navigating omnichannel growth.